



The Role of Immunotherapy in Hematological Malignancies Volume II

Guest Editor:

Prof. Dr. Marco Rossi

Department of Experimental and
Clinical Medicine, Magna Graecia
University of Catanzaro, 88100
Catanzaro, Italy

Deadline for manuscript
submissions:

15 December 2024

Message from the Guest Editor

Hematological malignancies have been the target of immunotherapy since the advent of allogeneic stem cell transplantation, which has shown for the first time the pros and cons of boosting immune responses against tumor cells and the surrounding tissues. Allogeneic donor lymphocyte infusions have proven that it is possible to further boost allo-immune responses to re-attain remissions when the previous tumor immune surveillance has been somewhat lost. Moving from the experience with leukemias, tumor immunotherapy has recently been enriched with the introduction of different therapeutics that rely on potentiating and/or refueling immunity (checkpoint inhibitors, moAbs, and bispecific antibodies) up to the design of engineered T cells that are empowered to recognize tumor antigens through chimeric receptors (CAR-T). Indeed, hematological malignancies represent an ideal target for such approaches due to the direct access to the tumor bed by immune cells. However, a main limitation is represented by the tumor driven immune-suppressive microenvironment, which can turn off immune responses.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)